Familial British dementia
| Familial British dementia | |
|---|---|
| Synonyms | FBD |
| Pronounce | N/A |
| Specialty | Neurology |
| Symptoms | Dementia, cerebellar ataxia, spasticity |
| Complications | N/A |
| Onset | Typically in the fifth decade of life |
| Duration | Progressive |
| Types | N/A |
| Causes | Mutation in the ITM2B gene |
| Risks | Genetic predisposition |
| Diagnosis | Genetic testing, neurological examination |
| Differential diagnosis | N/A |
| Prevention | N/A |
| Treatment | Supportive care |
| Medication | N/A |
| Prognosis | Poor, with progressive decline |
| Frequency | Very rare |
| Deaths | N/A |
Familial British dementia (FBD) is a rare form of dementia that is inherited in an autosomal dominant manner. It is characterized by progressive dementia, spasticity, and ataxia. The disease is caused by a mutation in the BRI2 gene.
Symptoms[edit]
The symptoms of Familial British dementia typically begin in mid-adulthood and progress slowly over the course of several years. They include:
Causes[edit]
Familial British dementia is caused by a mutation in the BRI2 gene. This gene provides instructions for making a protein that is found in many tissues, including the brain. The exact function of this protein is not known, but it is thought to play a role in the normal functioning of nerve cells (neurons).
Diagnosis[edit]
Diagnosis of Familial British dementia is based on the presence of characteristic clinical features and a family history of the disease. Genetic testing can confirm the diagnosis.
Treatment[edit]
There is currently no cure for Familial British dementia. Treatment is supportive and aimed at managing symptoms.